Prospera Financial Services Inc Cuts Position in Gilead Sciences, Inc. (GILD)
Prospera Financial Services Inc lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 63.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,197 shares of the biopharmaceutical company’s stock after selling 17,984 shares during the period. Prospera Financial Services Inc’s holdings in Gilead Sciences were worth $681,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the company. Hall Laurie J Trustee raised its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC raised its position in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the period. Lombard Odier Transatlantic Limited Partnership boosted its stake in Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 500 shares in the last quarter. First Bank & Trust bought a new stake in Gilead Sciences during the fourth quarter valued at approximately $140,000. Finally, Thomas J. Herzfeld Advisors Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at approximately $143,000. 74.19% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.05% during midday trading on Friday, reaching $64.46. 3,390,185 shares of the company were exchanged. Gilead Sciences, Inc. has a 52 week low of $63.88 and a 52 week high of $88.85. The firm has a market capitalization of $84.23 billion, a PE ratio of 6.81 and a beta of 1.11. The company has a 50-day moving average of $66.84 and a 200 day moving average of $70.67.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.66 billion. Equities analysts predict that Gilead Sciences, Inc. will post $8.21 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Investors of record on Friday, June 16th will be issued a $0.52 dividend. The ex-dividend date is Wednesday, June 14th. This represents a $2.08 annualized dividend and a dividend yield of 3.23%. Gilead Sciences’s payout ratio is currently 18.91%.
COPYRIGHT VIOLATION NOTICE: “Prospera Financial Services Inc Cuts Position in Gilead Sciences, Inc. (GILD)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/05/19/prospera-financial-services-inc-sells-17984-shares-of-gilead-sciences-inc-gild-updated.html.
GILD has been the topic of several analyst reports. Credit Suisse Group AG cut their price target on shares of Gilead Sciences from $93.00 to $79.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 8th. Barclays PLC restated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, February 9th. Berenberg Bank set a $78.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, February 14th. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $79.63 price objective on the stock in a research note on Tuesday, March 7th. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Monday, February 13th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $80.61.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $67.18, for a total value of $4,926,510.94. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at $214,973,917.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 30th. The stock was sold at an average price of $67.48, for a total value of $337,400.00. Following the sale, the executive vice president now owns 117,988 shares in the company, valued at approximately $7,961,830.24. The disclosure for this sale can be found here. Insiders sold 88,276 shares of company stock valued at $5,932,578 over the last 90 days. 1.40% of the stock is currently owned by corporate insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.